spacer
home > pmps > winter 2002 > improving the clinical trial supply chain by using best practice techniques
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Improving the Clinical Trial Supply Chain by Using Best Practice Techniques

What's the best way to ensure that clinical trial compounds are correctly packaged, labelled and delivered, while still maintaining tight control of costs? That's an increasingly critical question for companies in the pharmaceutical industry, where better manufacturing and supply processes can make the difference between a smooth and timely clinical trial and a costly debacle - drug makers lose up to a million US dollars in sales for each day a new drug's market launch is delayed.

As clinical studies become more complex and protracted, these supply chain issues grow even more pressing. To meet the challenge, leading pharmaceutical companies are implementing best practice processes, such as the deployment of cross-functional project teams. But many companies are still not using software tools to optimise production planning and execution.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Harald Geimer, Director of Worldwide Life Sciences and
Frank H Schulze, Principal of Worldwide Life Sciences Practice at PRTM

Harald Geimer is Director of Worldwide Life Sciences Practice at PRTM. He has over 14 years' consulting experience, primarily in supply chain management and product and process development, spanning the pharmaceutical, biotech, chemicals and medical devices industries.

Harald has led projects for companies to facilitate improvement in product development, supply chain management processes and outsourcing strategies. His consulting experience prior to joining PRTM, focused on business process re-engineering in the area of logistics, and marketing and service development in purchasing and supply management.

Harald holds a Masters Degree in Business Studies and Engineering from the Technical University in Darmstadt, Germany.

Frank H Schulze is Principal of Worldwide Life Sciences Practice at PRTM. He has 15 years of industry and consulting experience in developing business strategies and organisational concepts, sales and marketing, strategic product portfolio analysis, optimising R&D portfolios, integrating acquisitions and managing projects within the pharmaceutical, chemical, consumer and medical diagnostics industries. Prior to joining PRTM, Frank worked as General Manager of the Central and Eastern European Region for Hoechst Marion Roussel (now Aventis).

He was a Team Leader for the merger of Hoechst and Roussel in Europe and Latin America and managed the integration of Marion Merrill Dow (MMD). Frank also held senior management positions in several pharmaceutical and chemical companies. He has a PhD in Science from the Max-Planck-Institut in Gцttingen, Germany and a Masters Degree in Biology from the University of Heidelberg.


spacer
Harald Geimer
spacer
spacer
spacer
Frank H Schulze
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kindeva Drug Delivery, Formerly 3M Drug Delivery Systems, Launches as an Independent Company

Kindeva is a leading global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with a wealth of expertise in formulation, product development and manufacturing. Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company's microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement